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ABSTRACT
Introduction: Inodilators are the first-choice 
class of drugs for the treatment of acute heart 
failure (AHF). Levosimendan is a relatively recent 
inodilatory agent, presenting superior outcomes 
in comparison with traditional inotropes. 
Methods:  An economic evaluation of 
levosimendan for the treatment of AHF in 
Italy was performed. In a retrospective study 
conducted on patients with AHF admitted 
to a teaching hospital in Rome, two groups 
were derived from an observational registry: 
147 patients treated with levosimendan and 
145 treated with dobutamine. Follow-up was 
at 1 year after treatment. In the reference 
study looked at in this paper, treatment with 
levosimendan reduced mean length of stay 
(LOS) by 1.5 days (P < 0.05). Reduction in the 
rehospitalization rate was 6.7% (P < 0.05). 
Mortality rate at 1 month was reduced by 
4.8% (P < 0.05).
Results: Based on the reference study, a cost 
analysis from the hospital perspective was 
carried out. The incremental cost of treatment 
with levosimendan (€697) was equivalent to 
the incremental savings (€694), the latter being 
obtained from the reduction in LOS (€508) and 
rehospitalization rate (€186). 
Conclusion: Despite the limitations of this study, 
and even neglecting all nonmonetary health 
gains as additional outcomes, levosimendan 
appears to be a competitive alternative compared 
with dobutamine for the treatment of AHF in 
the Italian hospital setting. 
Keywords: Acute heart failure; Cardiology; 
Cost analysis; Heart failure; Inodilators; 
Italy;  Length of stay;  Levosimendan; 
Rehospitalization rate
C. Lucioni (*) · S. Mazzi 
Springer Healthcare, via Lanino 5, 20144, Milano, Italy 
e-mail: carlo.lucioni@springer.com
A. D’Ambrosi · F. Fedele 
Department of Cardiovascular, Respiratory, 
Nephrological, and Geriatric Sciences, La Sapienza 
University of Rome, Policlinico “Umberto I,” Rome, 
Italy
P. Pollesello · M. Apajasalo 
Orion Pharma, Orionintie 1A, Espoo, Finland
Enhanced content for Advances in Therapy 
articles is available on the journal web site: 
www.advancesintherapy.com 
1038 Adv Ther (2012)  29(12):1037–50.
suggesting a possible trend slowdown as has 
already occurred elsewhere [6, 7]. Since 2002, 
DRG 127 has been second in the ranking of 
the top 10 DRGs by number of admissions; 
yearly admissions corresponding to DRG 127 
amounted to 0.3% of the Italian population [8] 
and 2.6% of all hospitalizations of acute patients 
in regular wards [5]. 
The financial burden of HF is high. Direct 
medical costs (of which two-thirds are due to 
hospitalizations) are 1–2% of the overall health 
expenditure in developed countries [9]. In the 
USA, the estimated hospitalization costs in 
2008 amounted to $18.8 billion, corresponding 
to 0.9% of the overall health expenditure 
[1]. With regard to Italy in 2008, the tariff of 
DRG 127 was multiplied by the respective 
number of hospitalizations, and a cost value was 
obtained (€618 million), corresponding to 1.2% 
of the total hospital public expenditure [5, 8]. The 
tariff chosen for this estimate was the mean value 
of the regional DRG tariffs in Italy, weighted with 
the corresponding number of admissions [10].
In the management of AHF, an ideal strategy 
is to increase myocardial contractility without 
increasing oxygen consumption due to increased 
aortic pressure. This dual goal is pursued 
by inodilators, a class of drugs that increase 
contractility and cause vasodilatation [11]. 
Inodilators are the first-choice class of drugs 
for the treatment of AHF. Levosimendan is a 
relatively recent inodilatory agent combining 
positive inotropic and vasodilating actions 
through its calcium-sensitizing and potassium-
channel opening effects. The mechanism for 
such an accomplishment is novel [12, 13].
A number of studies have been published 
on the safety and efficacy of levosimendan, 
administered as  init ia l  t reatment to 
hospitalized patients. Indeed, the body of 
evidence is one of the largest ever produced 
regarding a new agent for the treatment 
INTRODUCTION
Among cardiovascular diseases, heart failure 
(HF) is sometimes referred to as a “final stage” 
condition. The prognosis is poor, with a 
mortality rate of approximately 50% within 
the first 5 years following diagnosis [1]. HF is 
a complex clinical syndrome that can result 
from any structural or functional cardiac or 
noncardiac disorder, which leaves the heart 
unable to pump blood to match the bodies 
requirements. Acute HF (AHF) may be either 
de novo HF or worsening (decompensation) of 
chronic HF, both requiring urgent care [2].
The incidence and prevalence of 
HF increases with age, affecting more women 
than men (higher incidence in women may 
be due to men dying earlier, typically from 
myocardial infarction). Therefore, with the 
ongoing aging of the population, the disease 
is more and more widespread, notably in the 
industrialized world [3]. In the USA in 2006, 
the prevalence of HF in the general population 
was approximately 2%, with hospitalizations 
amounting to 1.1 million (0.4%) [1].
Due to a lack of more specific data, the 
number of hospitalizations can be taken as an 
order of magnitude of the incidence of HF in 
Italy. A simplified but reliable indicator of the 
overall hospitalization activity for HF in Italy 
is the number of admissions in regular wards 
(including intensive care units [ICUs]/cardiac 
care units [CCUs], and excluding day hospitals), 
which are identified by the diagnosis-related 
group (DRG) code 127 (HF and shock). Data 
provided by this indicator for the years 2001 to 
2003 amounted to approximately 90% of total 
HF hospitalizations estimated in an ad-hoc study, 
with more refined methods for the same years in 
Italy [4]. This number increased from 170,765 
in 2000 to 198,614 in 2005 (+16.4%), and 
consequently to 203,885 in 2010 (+2.7%) [5], 
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present study was to perform an economic 




The present analysis uses Italian clinical data. 
It is based on a retrospective study conducted 
on patients with AHF who had been admitted 
to a major teaching hospital located in Rome 
(the Department of Cardiovascular, Respiratory, 
Nephrologic and Geriatric Sciences, “La 
Sapienza” University of Rome, Policlinico 
“Umberto I”) [21]. Between July 2006 and 
April 2009, the clinic treated 908 patients 
with AHF. A total of 147 consecutive patients 
treated with an infusion of levosimendan were 
derived from the observational registry, with a 
of AHF [14]. The main studies are summarized 
in chronological order in Table 1 [15–20]. 
In a recent literature review of intravenous 
levosimendan, all 45 randomized clinical trials 
published on levosimendan and reporting 
mortality data were selected (which included 
5,480 patients), and an in-depth meta-analysis 
was performed (the most comprehensive 
and statistically robust to date) [14]. The 
most frequent comparators were dobutamine 
or placebo, and other comparators were 
other inodilators (milrinone, enoximone), 
prostaglandin E1, or no comparator. The 
findings showed, both overall and in different 
subgroups, survival gains in patients receiving 
levosimendan and a reduction in length of stay 
(LOS) in patients treated for AHF. 
Despite these gains, when compared with 
dobutamine, levosimendan is perceived as an 
expensive alternative. The objective of the 
Table 1  Major studies on levosimendan




Results (for levosimendan) Reference
LIDO 203 Dobutamine 6 Better hemodynamic performance and 
lower mortality 
[15]
RUSSLAN 504 Placebo 6 Reduced risk of worsening heart failure  
and death
[16]
CASINO 199 Dobutamine, 
placebo
6 Improved survival [17]
REVIVE II 600 Placebo 3 Improved clinical status [18]
SURVIVE 1,327 Dobutamine 6 No significant reduction in all-cause 
mortality
[19]
CASINO Calcium Sensitizer or Inotrope or None in Low-Output Heart Failure Study, LIDO Levosimendan Infusion 
versus Dobutamine study, PERSIST Oral levosimendan in patients with severe chronic heart failure, REVIVE 
Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short-Term Treatment 
of Decompensated Heart Failure, RUSSLAN Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients 
with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study, 
SURVIVE Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support Study 
a Levosimendan was administered intravenously (bolus or continuous infusion) similar to most published trials.  
The PERSIST study [20] is not included here because levosimendan was administered orally
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follow-up of 1 year after treatment. As a control 
group, 145 patients with well-matched baseline 
characteristics [21] who had been treated with 
dobutamine in the same unit and over the same 
period of time were identified a posteriori. The 
use of established therapies, such as angiotensin-
converting enzyme inhibitors, diuretics, and 
beta-blockers, was permitted in both groups. 
The assignment of each patient to the initial 
treatment (levosimendan or dobutamine) had 
been made with no randomization process and 
on the judgement of the attending cardiologist. 
The mean LOS was significantly (P < 0.05) 
shorter in the levosimendan group (12.1 days) 
than in the dobutamine group (13.6 days), with 
a reduction of 1.5 days (P < 0.05). Favorable 
outcomes in the former group were also achieved 
with regard to the mortality rate at 1 month 
(2.1% vs. 6.9%; P < 0.05; rate reduction: 4.8%) 
and the readmission rate at 12 months (7.6% vs. 
14.3%; P < 0.05; rate reduction: 6.7%). 
The Economic Analysis
The present evaluation was conducted as a cost 
analysis (though not as a cost-minimization 
analysis, since efficacy is not equal between the 
competing treatments considered here). In this 
approach, the comparative costs and savings of 
alternative treatments were analyzed from the 
perspective of the payer [22]. This analysis did 
not take into account the above-mentioned 
benefits of levosimendan in improving 
symptoms and reducing mortality versus 
dobutamine. Instead, its approach allowed 
the payer to assess the economic impact of 
levosimendan treatment and to make a rational 
choice among alternatives. 
The economic evaluation was performed from 
the hospital perspective, comparing hospital 
costs with levosimendan versus dobutamine 
treatment. The cost of levosimendan is not 
reimbursed by the Italian National Health 
Service (NHS) to hospitals where the drug is 
administered to patients with AHF. In strict 
budgetary terms, it would then make no 
difference to the NHS whether levosimendan is 
used as an alternative to other inodilators or not, 
as no incremental payment would, in any case, 
be borne by the NHS. Accordingly, the economic 
perspective of the analysis cannot be that of the 
NHS; it has to be shifted to the hospital – the 
real decision-maker and payer for the use of 
levosimendan (levosimendan has been approved 
in Italy for hospital use only). 
Possible Cost Savings for Hospitals from 
Better Effectiveness of Levosimendan 
Considering drug costs only, a hospital might 
not be inclined to choose levosimendan because 
of its relatively high (and not reimbursed) 
acquisition cost. However, the situation might 
be different if the incremental drug cost was 
offset by the savings coming from the superior 
effectiveness of the drug compared to other 
treatments; such savings would either be in the 
form of cost reduction (from LOS reduction) 
or in the form of more revenues (from reduced 
rehospitalization rate).
Savings from LOS Reduction
A DRG tariff is constant (up to a point), and a 
hospital is paid even when variable costs for 
the patient’s care cease following discharge. 
Such “undue” coverage (arising when the 
patient is discharged in advance compared to 
a LOS taken as reference) corresponds to a gain 
for the hospital. This is not true with regard 
to fixed costs, such as overheads and medical 
staff, which are not linked to individual 
hospitalizations; in this case, the coverage 
of such costs by the DRG tariff is justified 
regardless of the actual LOS.
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Ideally, savings in the variable costs due to LOS 
reduction should be measured on the basis of the 
average variable cost per day of a patients stay 
(including drugs, subsidiaries, diagnostic tests 
and procedures, and hotel costs), with reference 
to a cardiology department. However, as these 
types of specific data are generally unavailable 
in Italy (or ad-hoc research would be required), 
they were evaluated in the present study using 
the above-mentioned gain as a proxy. For the 
sake of precision, it should be pointed out that 
an average value would overestimate the correct 
value, due to the right-skewed distribution of 
the variable cost as a function of the in-patient 
stay time [22]. However, a precise estimate could 
not be attained in the present study.
Savings from a Reduction in Rehospitalization 
Rate
As far as a full occupancy assumption can 
be made of beds in a cardiology department, 
further savings might be derived from the 
superior effectiveness of levosimendan. The 
reduction of the rehospitalization rate means 
that fewer admissions for AHF (i.e., classified 
with DRG 127) will occur in the department. If 
the beds released are then occupied by patients 
with a higher (on average) DRG tariff, there 
would be revenue for the hospital. The point 
is then to compare the DRG 127 tariff with the 
average tariff calculated on the DRG mix in the 
department.
In contrast, without a full bed occupancy 
situation, that is in a context with lesser demand 
for hospitalizations, new admissions would not 
need to compete for beds. In this sense, the 
reduced rehospitalization rate of admissions 
classified with DRG 127 would provide no 
additional revenue to the hospital. 
A numerical example might be useful to grasp 
this issue. As a start, the authors assume that a 
cardiology department is equipped with 100 beds 
and works at 100% occupancy. In this case, a 
10% reduction in the rehospitalization rate when 
patients are treated with levosimendan means 
that 10 beds will be released and will most likely 
be occupied by other patients, with an expected 
disease distribution according to the activity 
mix of the department. Whereas, if the 100 beds 
occupancy is at 90%, by definition the 10 beds 
left free will remain redundant. If the occupancy 
is at 95%, 95 beds will be occupied and five will 
remain unoccupied. On these grounds, the 
necessary condition for additional revenue from 
the discussed reduction in rehospitalization 
rate could be formulated as: occupancy rate 
>100% – reduced rehospitalization rate. If the 
reduction in rehospitalization rate is ≤0 then 
the condition cannot be satisfied and there is no 
revenue. Otherwise, if the condition is satisfied, 
if occupancy rate = 100% then the revenue is 
full; if occupancy rate <100% then the revenue 
can only be partial.
However, the situation is not exactly like this 
in practice. The reason is that the department 
activity involved with DRG 127 (that is, where 
the reduction in rehospitalization rates occurs) 
is generally only a subset of the whole activity 
of the department, which has a mix of DRGs. 
Therefore, a rate reduction of 10% does not 
mean 10 beds are left free; fewer beds will be 
free because that rate does not refer to the 100 
beds of the whole department, but only to 
the subset with DRG 127. The number of beds 
actually released will ultimately depend on the 
proportion of the number of admissions for 
AHF divided by the total number of admissions 
included in the mix of the department.
The Model 
The present analysis was of an incremental type, 
confronting the cost difference between the 
two in-hospital therapies (levosimendan and 
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dobutamine, respectively) with the analogous 
savings difference. Costs and savings are referred 
to one patient/treatment case. The outcome of 
the analysis can then be defined as:
NS = (SL – SD) – (CL – CD)
The definitions in the model are: net savings 
(NS); savings from using levosimendan (SL); 
savings from using dobutamine (SD); cost 
for using levosimendan (CL); cost for using 
dobutamine (CD).
Costs
With regard to treatment costs, in the present 
study the DRG 127 tariff is considered as a 
proxy of the costs borne by a hospital for the 
hospitalization of one patient with AHF. As such, 
we have: 
CL = T127 + VL
CD = T127
The definitions in the model are: DRG 127 
tariff (T127); cost of one vial of levosimendan, not 
included in the DRG 127 tariff (VL).
Savings
With regard to the savings, the DRG 127 tariff 
(defined in the model as T127) is to be considered 
as the revenue a hospital receives for the 
hospitalization of a patient with AHF. This kind 
of revenue is common to both therapies.
Furthermore, there are two possible savings 
(for levosimendan therapy only) stemming from 
its higher effectiveness. 
Savings from LOS Reduction
The savings corresponding to each discharge 
occurring in advance due to levosimendan 
are evaluated in two steps. First, a nominal 
“daily” DRG tariff is calculated by dividing the 
DRG 127 tariff by the average LOS. Second, 
the result is multiplied by the LOS reduction; 
i.e., by the number of days for which the 
hospital is reimbursed after the patient has 
been discharged (1.5 days in the reference 
study [21]). The definition used in the 
model is: savings from LOS reduction due to 
levosimendan (SLOS). 
As already pointed out, such additional 
revenue is not net revenue. Actually, only a quota 
should be taken into account corresponding to 
the variable costs, but this operation is hardly 
feasible as, as already stressed, variable costs 
in a hospital department are very difficult 
to estimate. Consequently, the savings are 
overestimated.
Savings from a Reduction in Rehospitalization 
Rate
Clearly, the additional revenue for each 
treatment with levosimendan (instead of 
dobutamine) is not the entire difference 
between the average tariff of the DRG mix in the 
cardiology department and the DRG 127 tariff. 
It would only be so when any treatment with 
dobutamine was followed by a rehospitalization 
and any treatment with levosimendan was 
followed by no rehospitalization (i.e., if 
the reduced rehospitalization rate due to 
levosimendan was 100%). Instead, the amount 
will be proportional to the actual reduction 
assessed in the rehospitalization rate (6.7% 
in the reference study [21]). Such amount is 
defined in the model below (savings from 
rehospitalization rate reduction due to 
levosimendan [SRRR]).
Total savings:
SL = T127 + SLOS + SRRR
SD = T127
Net savings:
NS = (SL – SD) – (CL – CD)
NS = [(T127 + SLOS + SRRR) – T127] – 
[(T127 + VL) – T127]
NS = SLOS + SRRR – VL
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Further Data
In order to evaluate the magnitude and the 
plausibility of the above mentioned savings, 
the authors obtained further administrative 
data (Table 2) from the cardiology department of 
the “Umberto I” hospital.
These data were preliminarily processed for 
analysis. Average annual values were calculated 
between the 2 years reported (in order to 
simplify the analysis from cumbersome yearly 
details) and between the two settings (regular 
ward and ICU) to enable linking with the 
outcomes from the reference study (which are 
at the whole department level). The number of 
admitted patients was used for weighting LOS 
and bed occupancy rate data from the respective 
settings, and the number of discharged patients 
for weighting revenue data. 
From the same source, the number of patients 
treated for AHF between 2006 and 2009 was 
obtained. 
Unit Costs
The cost for one vial of levosimendan (€697) 
was taken from the reference study [21].
Following devolution of healthcare 
management from a national to a regional base, 
variation can be found among the local tariffs 
of a given DRG. With regards to DRG 127, an 
average data for Italy (€3,079) was calculated on 
the 2008 regional tariff values [8], weighted with 
the corresponding number of admissions [5]. 
The national average LOS (9.1 days), which was 
used to estimate a nominal “daily” DRG tariff, 
was also drawn from the same source [5]. In 
particular, the average revenue per discharged 
patient (based on data in Table 2) was adopted 
as a proxy for the average tariff of the DRG mix 
in the cardiology department (€5,885).
Sensitivity Analysis
The impact of possible variations in the 
estimated inputs of the model was tested with 
a one-way deterministic analysis. With regard 
to the reduction of LOS due to levosimendan, 
the low and high values of its 95% confidence 
intervals (CI) were respectively assumed. 
A similar approach was adopted for the reduction 
of the rehospitalization rate.
The nominal “daily” DRG 127 tariff 
overestimates the real savings from LOS 
reduction, because it includes a fixed-costs quota, 
Table 2  “Umberto I” hospital: activity indicators for the cardiology department
Indicatorsa Regular ward ICU
2009 2010 2009 2010
Admitted patients, n 851 815 223 226
Discharged patients, n 1,032 976 97 108
LOS, days 7.0 7.7 13.2 11.4
Bed occupancy rate, % 100.7 99.1 97.1 100.6
Average revenue per discharged patient, € 5,615 5,562 8,094 8,810
ICU intensive care unit, LOS length of stay
a The discrepancies within each setting between admitted and discharged patients are chiefly explained by considering 
that many patients who are admitted to the ICU are later transferred to the regular ward, from which they are eventually 
discharged. Other inter-hospital transfers, as well as stays extending from 1 year to the following year, can account for the 
residual explanation
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which cannot be considered additional revenue. 
As the real amount of such quota could not 
easily be known, the value inputted in the 
base case model was halved, as an approximate 
adjustment, in the sensitivity analysis.
The impact of a full occupancy assumption on 
savings due to the reduction in rehospitalization 
rate was tested conjecturing that in the narrow 
interval of a 100% occupancy the attenuation 
of the assumption might imply that the 
savings specifically due to the reduction in 
rehospitalization rates would linearly decrease 
from their full amount (corresponding to 100% 
occupancy) to zero (with occupancy outside 
the neighbourhood region). The neighborhood 
region was indicatively set between 100% 
and 100% minus 1.5%. The ratio between the 
number of hospitalizations with DRG 127 and 
the total number of hospitalizations with all 
DRGs related to cardiocirculatory diseases was 
Table 3  Costs and savings (per one patient/treatment) 
Levosimendan Dobutamine Incremental values
Costs for treatment
DRG 127 tariff (proxy for one hospitalization cost with 
standard care), €
3,079 3,079 0
Cost for one vial of levosimendan, € 697 0 697
Total costs, € 3,776 3,079 697
Savings from treatment
DRG 127 tariff (revenue from one hospitalization cost 
with standard care), €
3,079 3,079 0
Savings from LOS reduction
Average LOS, days 9.1
Nominal “daily” tariff (of DRG 127), € 338
LOS reduction due to levosimendan, days 1.5
Additional revenue from LOS reduction due to 
levosimendan, €
508 0 508
Savings from rehospitalization rate reduction
Average revenue per discharged patient (proxy for average 
tariff of DRG mix), €
5,885
Difference between DRG mix and DRG 127 tariffs, € 2,776
Reduction in rehospitalization rate due to levosimendan, % 6.7
Additional revenue from reduced rehospitalization rate 
due to levosimendan, €
186 0 186
Total savings, € 3,773 3,079 694
Net savings, € –3 0 –3
DRG 127 diagnosis-related group code 127 (heart failure and shock), LOS length of stay
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about one-fifth in Italy in 2009 [10]. Assuming 
this ratio could approximately represent the 
analogous activity proportion in a cardiology 
department, it was used to weigh the reduction 
in rehospitalization rates (6.7%), obtaining 
approximately 1.5%.
The net savings of levosimendan versus 
dobutamine were then calculated for three 
scenarios:
1. 100% bed occupancy, corresponding to full 
savings from reduced rehospitalization rate 
due to levosimendan (base case)
2. 99.25% occupancy, corresponding to half 
savings




The incremental cost of the treatment with 
levosimendan (€697; i.e., the cost for one vial) 
is in balance with the incremental treatment 
savings (€694) (Table 3). This benefit is the sum 
of two addends: the major addend (€508) stems 
from the LOS reduction (1.5 days), the 
other addend (€186) from the reduction in 
rehospitalization rate (6.7%). 
Sensitivity Analysis
The outcomes from the sensitivity analysis 
are reported by decreasing order of impact 
magnitude in Table 4.
In the base case, the net savings value is 
approximately zero; as such, net savings resulting 
from the sensitivity analysis may sometimes 
take opposite values (positive/negative with 
respect to zero). More generally, in unfavorable 
conditions the cost of levosimendan is only 
partially balanced by savings. 
Economic results appear to be most sensitive 
to LOS reduction (1.5 days). When such 
reduction was set at the highest value reasonably 
assumable (corresponding to the 95% CI higher 
limit), the treatment net benefit would increase 
to €470; whereas at the lowest value the loss 
would be as big, in absolute value. Of course, 
these values represent only the two extremes in 
the distribution of the likely net benefit values 
as a function of LOS reduction. 
Table 4  Sensitivity analysis
Variation range Net savings at 
lower limit, €




LOS reduction 95% CI –474 470 944
Reduction in rehospitalization rate 95% CI –187 180 367
















CI confidence interval, DRG 127 diagnosis-related group code 127 (heart failure and shock), LOS length of stay
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Relaxing the assumption of full occupancy 
in a cardiology department (i.e., considering an 
occupancy rate ≤98.5%), the net savings would 
be negative (–€189). 
DISCUSSION
The present cost analysis was performed in 
order to evaluate the economic impact of 
levosimendan versus dobutamine for the 
treatment of AHF, from the perspective of an 
Italian hospital. This perspective was chosen on 
consideration that the cost of levosimendan is 
not reimbursed to hospitals by the Italian NHS, 
so an analysis from the perspective of the NHS 
would not be realistic. Actually, levosimendan 
is not a new treatment, which is not currently 
reimbursed but is expected to become so. In 
this instance, it would make sense conducting 
an analysis from the NHS perspective by 
including the cost of the drug as the requested 
reimbursement price. On the contrary, 
levosimendan’s life in the market has already 
reached the maturity phase, which makes it 
unlikely that a change in its reimbursement 
profile will happen. 
This analysis exploits the real hospitalization 
outcomes from an Italian retrospective study [21]. 
As far as comparison is possible, such outcomes 
appear to be in line with those which are 
reported in published clinical trials of 
levosimendan [15–19] and in a comprehensive 
meta-analysis [14], in particular with regards to 
shortened LOS; the gain of 1.5 days reported 
by Fedele et al. [21] is the same as that reported 
by Landoni et al. [14]. In other words, all 
these clinical findings appear to be confirmed 
by a “real-life” clinical experience in Italy. 
A similar appraisal can be formulated about 
the consistency between the present analysis 
results and the conclusions of various economic 
evaluations of levosimendan [23–26].
Some limitations are present in the current 
analysis, mainly regarding the generalizability of 
its results. In fact, the sample size is reduced to 
one center, though of primary importance. Also, 
the plausibility of a full occupancy assumption 
in a cardiology department, introduced in 
the analysis to estimate savings from reduced 
rehospitalization rates, is confirmed only in 
the hospital where the reference study was 
conducted. On the other hand, for more general 
information no useful statistical sources were 
found. Ad-hoc questionnaires should otherwise 
have been administered to a sample of hospitals. 
In any case, the results of the present analysis 
can be correctly applied in a given cardiology 
department only after having tested its 
occupancy level. 
Again, with regard to the study sample, 
the fact that the assignment of each patient 
to the initial treatment was made on the 
judgement of the attending cardiologist 
might have created a bias. Confounding by 
indication is a bias frequently encountered in 
observational epidemiologic studies of drug 
effects. Because the allocation of treatment in 
observational studies is not randomized and 
the indication for treatment may be related 
to the risk of future health outcomes, the 
resulting imbalance in the underlying risk 
profile between treated and comparison groups 
can generate biased results [27]. However, 
the consideration could be made that an 
expensive drug, like levosimendan, is given to 
the sicker patients, which would represent a 
“conservative” bias. 
With regard to savings from LOS reduction, 
resulting data is to some degree overestimated 
since the calculation method which, for lack of 
specific information, had to be adopted bypasses 
the problem that the cost distribution is not 
uniform in time, but shifted to higher values 
in the first days. Due to this flaw, and to the 
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modest proportion of the number of days saved 
compared to the whole LOS, savings may have 
a lower impact. 
Another limitation relates to unit cost data, 
which were preferably adopted at the national 
level (because this was more appropriate for the 
generalizability of results). There is, however, a 
lack of homogeneity between the tariff value 
adopted for the DRG 127 (a value at the national 
level) and the average revenue per discharged 
patient (a value assessed in the “Umberto I” 
hospital). The latter value was taken as a proxy 
of an average tariff of the DRG mix in an Italian 
cardiology department due to the difficulty of 
achieving a realistic estimate.
Using the reimbursement DRG tariffs 
as proxies of the true hospital costs is an 
approach that, though largely adopted at least 
in Italian research, is not recommendable as 
a method. However, it should be considered 
that true cost data were unavailable at the 
reference hospital, as is generally the case at 
most Italian sites. Moreover, this approach 
might be appreciated as far as true hospital 
costs vary from hospital to hospital; namely, 
faced with such variation, using the DRG 
tariff as a proxy could be accepted as a 
generalization, allowing a broader perspective 
in the analysis than the mere hospital where 
the study was performed. 
The cost of dobutamine was not taken 
into account due to its relatively weak impact 
(treatment with the generic drug would only cost 
approximately €4.5 per patient) and assuming 
that, unlike levosimendan, it is reimbursed to 
hospitals through the DRG 127 tariff. Ultimately, 
costs were substantially balanced with savings in 
the present analysis.
A further benefit from the reduction in 
rehospitalization rate might be considered. 
The authors consider the preservation of the 
quality of life when a hospitalization (or, more 
specifically, the emergency that causes it) is 
avoided as an advantage for the patient and for 
the hospital. The considerations which follow 
have no pretension to extrapolate the results of 
this analysis to cost-effectiveness decisions; they 
are only aimed at giving some more, indicative 
elements of evaluation.
A quality-adjusted life year (QALY), 1 year 
of life in full health, can be given different 
monetary values [22]. The value conservatively 
considered in the present study corresponds to 
the lower limit of the range (€25,000–40,000 per 
QALY gained) indicated by Associazione Italiana 
di Economia Sanitaria (AIES) guidelines [28] as a 
threshold for the acceptability of a new health 
technology. AIES guidelines refer to threshold 
values implicitly or explicitly used in health 
systems comparable to the Italian NHS [29]. 
One-tenth of such amount (i.e., €2,500) could 
then be assumed as a rough measure of the value 
of a 10% change in a subject’s quality of life. 
No elicitation was performed in the reference 
study [21] on health state utility values in AHF, 
so data from other sources, which shall be 
reported here, have a purely orientative value. 
In a study conducted from 1977 to 1997 in 
the UK, 5,102 patients with newly diagnosed 
type 2 diabetes were recruited [30]. For those 
patients who had experienced no diabetes-
related complications, the mean tariff value 
(based on EuroQol Group [EQ]-5D utilities) for 
quality of life was 0.785. For a patient with a 
history of HF, the impact on such value was 
–0.108, corresponding to a loss in quality of life 
of about 14%. 
A recent original research conducted in Italy 
presented that moving from a general health 
condition (mean tariff: 0.906) to a postinfarction 
condition (mean tariff: 0.727) resulted in a loss 
of approximately 20% of a patients quality of 
life. Moreover, it takes at least 1 year to make up 
for this loss [31].
1048 Adv Ther (2012)  29(12):1037–50.
Also in this latter study, the limitations in 
comparability are strong; the quality of life of 
a patient with AHF is lower than the general 
populations, and the AHF condition is different 
from a myocardial infarction. But in light of 
the study, as a first approximation, avoiding a 
hospitalization due to AHF might reasonably 
be worth €2,500 (as this amount was assumed 
to correspond to a 10% change in quality of 
life, which is smaller than a 20% loss due to a 
cardiovascular event) [31].
Following one treatment with levosimendan, 
rehospitalization is reduced by 6.7% (compared 
with dobutamine [21]). In these terms, a €2,500 
× 6.7% = €165 additional gain could be deemed 
to correspond to that treatment. Of course, such 
benefit would be outside the hospital’s strictly 
economic perspective (for this reason, it has 
been discussed but not included in the core of 
the evaluation). On the other hand, it should 
not be completely neglected by a decision maker 
who, like a hospital manager, is committed to 
patients’ health and their health-related quality 
of life.
In accordance with this kind of argument, 
the reduction in the mortality rate at 1 month 
as a result of the treatment with levosimendan 
(2.1% vs. 6.9% [21]) should be appreciated too. 
Considering that in 2010 approximately 200,000 
hospitalizations occurred with DRG 127 [5], 
almost 10,000 patients could be saved from 
death (at least at 1 month) every year. Notably, 
the survival benefits observed in the Italian 
study match those in the recent comprehensive 
meta-analysis [14]. 
CONCLUSION
For all the limitations discussed in this analysis, 
levosimendan appears to be a competitive 
alternative to dobutamine for the treatment of 
AHF in an Italian hospital setting.
ACKNOWLEDGMENTS
The study and article processing charges were 
funded by a grant from Orion Pharma Srl. The 
sponsor played no part in the study design or 
conduct; collection, analysis, interpretation of 
data; writing of the report; or in the decision to 
submit the paper to Advances in Therapy. The 
authors’ work was independent of the funding 
provider.
All authors contributed to the design, 
analysis, and interpretation of data, had full 
access to all of the data, and were involved in 
drafting the article. All authors revised the article 
and provided final approval of the version to be 
published. Dr. Lucioni is the guarantor for this 
article, and takes responsibility for the integrity 
of the work as a whole. Native English editing 
was provided by Mary Hines, of inScience 
Communications, Springer Healthcare. 
Conflict of Interest. Piero Pollesello and 
Marjo Apajasalo are employees of Orion Pharma. 
The remaining authors have no conflicts of 
interest to declare. 
Open Access. This article is distributed under 
the terms of the Creative Commons Attribution 
Noncommercial License which permits any non-
commercial use, distribution, and reproduction 
in any medium, provided the original author(s) 
and source are credited.
REFERENCES
1. Rosamond W, Flegal K, Furie K, et al; American 
Heart Association Statistics Committee and 
Stroke Statistics Subcommittee. Heart disease and 
stroke statistics–2008 update: a report from the 
American Heart Association Statistics Committee 
and Stroke Statistics Subcommittee. Circulation. 
2008;117:e25–146.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al; 
ESC Committee for Practice Guidelines (CPG). 
ESC Guidelines for the diagnosis and treatment 
Adv Ther (2012)  29(12):1037–50. 1049
of acute and chronic heart failure 2008: the Task 
Force for the Diagnosis and Treatment of Acute 
and Chronic Heart Failure 2008 of the European 
Society of Cardiology. Developed in collaboration 
with the Heart Failure Association of the ESC 
(HFA) and endorsed by the European Society of 
Intensive Care Medicine (ESICM). Eur Heart J. 
2008;29:2388–442.
3. Liao L, Allen LA, Whellan DJ. Economic burden of 
heart failure in the elderly. Pharmacoeconomics. 
2008;26:447–62.
4. Gigli G, Lispi L, Donati C, et al. Trends in 
hospitalization for heart failure in Italy 2001–2003. 
J Cardiovasc Med. 2009;10:367–71.
5. Ministero della Salute. Ricoveri ospedalieri (SDO). 
Banca dati. 2010. Available at: http://www.salute.
gov.it/ricoveriOspedalieri/ricoveriOspedalieri.jsp. 
Accessed Nov 23 2012.
6. Stromberg A, Dahlstrom U. Heart failure clinics 
have decreased mortality and hospitalisation rates 
in Sweden. Eur Heart J. 2004;25:1368–9; author 
reply 1368.
7. Najafi F, Jamrozik K, Dobson AJ. Understanding 
the ‘epidemic of heart failure’: a systematic review 
of trends in determinants of heart failure. Eur J 
Heart Fail. 2009;11:472–9.
8. ISTAT. Annuario Statistico Italiano. 2011. 
Available at: http://www3.istat.it/dati/
catalogo/20111216_00/. Accessed Apr 19 2011.
9. Berry C, Murdoch DR, McMurray JJ. Economics of 
chronic heart failure. Eur J Heart Fail. 2001;3:283–91.
10. Agenzia nazionale per i servizi sanitari regionali. 
Ricoveri per acuti in regime ordinario – Tariffe 
regionali massime. 2008. Available at: http://www.
agenas.it/monitoraggio_costi_tariffe/Ricoveri% 
20Acuti%20Tariffe%20regionali%202008.pdf. 
Accessed Nov 23 2012.
11. Marino P, Sutin KM. Acute heart failure syndromes. 
In: The ICU Book. 3rd edition. Philadelphia: 
Lippincott Williams & Wilkins; 2006.
12. Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. 
Pharmacological mechanisms contributing to the 
clinical efficacy of levosimendan. Cardiovasc Drug 
Rev. 2005;23:71–98.
13. Papp Z, Edes I, Fruhwald S, et al. Levosimendan: 
Molecular mechanisms and clinical implications: 
Consensus of experts on the mechanisms of action 
of levosimendan. Int J Cardiol. 2012;159:82–7.
14. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects 
of levosimendan on mortality and hospitalization. 
A meta-analysis of randomized controlled studies. 
Crit Care Med. 2012;40:634–46.
15. Follath F, Cleland JG, Just H, et al; Sterring 
Committee and Investigators of the Levosimendan 
Infusion Versus Dobutamine (LIPO) Study. Efficacy 
and safety of intravenous levosimendan compared 
with dobutamine in severe low-output heart failure 
(the LIDO study): a randomised double-blind trial. 
Lancet. 2002;360:196–202.
16. Moiseyev VS, Poder P, Andrejevs N, et al; RUSSLAN 
Study Investigators. Safety and efficacy of a novel 
calcium sensitizer, levosimendan, in patients with 
left ventricular failure due to an acute myocardial 
infarction. A randomized, placebo-controlled, 
double-blind study (RUSSLAN). Euro Heart J. 
2002;23:1422–32.
17. Zairis M, Apostolatos C, Anastasiadis P, et al. The 
effect of a calcium sensitizer or an inotrope or 
none in chronic low output decompensated heart 
failure: Results from the calcium sensitizer or 
inotrope or none in low output heart failure study 
(CASINO). J Am Coll Cardiol. 2004;43(5 Suppl. 
1):A206–A7.
18. Packer M. REVIVE II Trial Investigators: REVIVE 
II: Multicenter placebo-controlled trial of 
levosimendan on clinical status in acutely 
decompensated heart failure. Circulation. 
2005;112:3363.
19. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE 
Investigators. Levosimendan vs dobutamine 
for patients with acute decompensated heart 
failure: the SURVIVE Randomized Trial. JAMA. 
2007;297:1883–91.
20. Nieminen MS, Cleland JG, Eha J, et al. Oral 
levosimendan in patients with severe chronic 
heart failure – the PERSIST study. Eur J Heart Fail. 
2008;10:1246–54.
21. Fedele F, D’Ambrosi A, Bruno N, Caria C, Brasolin 
B, Mancane M. Cost-effectiveness of levosimendan 
in patients with acute heart failure. J Cardiovasc 
Pharmacol. 2011;58:363–6.
22. Drummond M, Sculpher M, Torrance G, et al. 
Methods for the economic evaluation of health care 
programmes. Oxford: Oxford University Press; 2005.
23. Oliveira MT, Jr., Follador W, Martins ML, et al. Cost 
analysis of the treatment of acute decompensated 
heart failure. Levosimendan versus dobutamine. 
Arq Bras Cardiol. 2005;85:9–14.
1050 Adv Ther (2012)  29(12):1037–50.
24. de Lissovoy G, Fraeman K, Salon J, Chay 
Woodward T, Sterz R. The costs of treating acute 
heart failure: an economic analysis of the SURVIVE 
trial. J Med Econ. 2008;11:415–29.
25. de Lissovoy G, Fraeman K, Teerlink JR, et al. 
Hospital costs for treatment of acute heart failure: 
economic analysis of the REVIVE II study. Eur J 
Health Econ. 2010;11:185–93.
26. Ebner C, Hörmann C, Pölzl G, et al. Levosimendan 
(Simdax®): A cost-effective treatment option for acute 
heart failure. Wiener Klinisches Magazin. 2011;2:1-4.
27. Signorello LB, McLaughlin JK, Lipworth L, Friis S, 
Sørensen HT, Blot WJ. Confounding by indication 
in epidemiologic studies of commonly used 
analgesics. Am J Ther. 2002;9:199–205.
28. Italian Health Economics Association (AIES) 
working group. Proposta di linee guida per la 
valutazione economica degli interventi sanitari 
in Italia. PharmacoEconomics – Italian Research 
Articles. 2009;11:83–93.
29. McCabe C, Claxton K, Culyer AJ. The NICE 
cost-effectiveness threshold: What it is and 
what that means. Pharmacoeconomics. 
2008;26:733–44.
30. Clarke P, Gray A, Holman R. Estimating utility 
values for health states of type 2 diabetic patients 
using the EQ-5D (UKPDS 62). Med Decis Making. 
2002;22:340–9.
31. Paletta T, Lucioni C, Volpe M. L’EuroQol 
(EQ-5D) per la misura dell’utilità negli 
studi di farmacoeconomia: Considerazioni 
metodologiche applicate al caso del paziente 
in dimissione dopo infarto miocardico. 
PharmacoEconomics – Italian Research Articles. 
2010;12:51–9.
